Tzuyung Douglas Kou, PhD, Mph, Ma.
About Tzuyung Douglas Kou, PhD, Mph, Ma.
Tzuyung Douglas Kou, PhD, MPH, MA, is the Executive Director and Head of Epidemiology for Global Patient Safety at BeiGene USA, Inc., based in Philadelphia, Pennsylvania.
Company
Currently, Tzuyung Douglas Kou works at BeiGene USA, Inc., a biopharmaceutical company. He holds the position of Executive Director, Head of Epidemiology, Global Patient Safety. BeiGene is located in Philadelphia, Pennsylvania, United States. The company focuses on molecularly targeted and immuno-oncology drug development. Kou's role is integral in BeiGene, leading epidemiological research and ensuring patient safety across their global operations.
Title
Tzuyung Douglas Kou holds the title of Executive Director and Head of Epidemiology for Global Patient Safety at BeiGene USA, Inc. In this senior role, he leads observational research, evaluates therapeutic area strategies, and oversees global patient safety protocols. His leadership in these domains assists BeiGene in integrating epidemiology into both the drug development process and post-marketing safety evaluations.
Education and Expertise
Tzuyung Douglas Kou has a robust academic background with a PhD in Clinical Epidemiology, an MPH in Epidemiology, and an MA in Medical Ethics from Case Western Reserve University School of Medicine. Additionally, he holds a BA in Biology from Hiram College and completed his high school diploma at Singapore American School. His academic accomplishments and professional training have equipped him with deep expertise in epidemiology, medical ethics, and pathology.
Background
Tzuyung Douglas Kou has an extensive professional background, including roles at Bristol Myers Squibb, Drexel University School of Public Health, Merck, Procter & Gamble, and Case Western Reserve University. His experience spans senior positions in epidemiology, risk management, and public health, contributing to his current leadership role in BeiGene. Previously, he led significant initiatives such as the Real World Evidence Strategy at Bristol Myers Squibb and served as an Adjunct Assistant Professor at Drexel and Case Western.
Achievements
Tzuyung Douglas Kou has notable achievements in the field of epidemiology and patient safety. He contributed to the European Commission's approval of BRUKINSA® (zanubrutinib) for treating chronic lymphocytic leukemia. At BeiGene, he improves clinical research design, anticipates and manages clinical safety issues, and provides strategic leadership. His role involves influencing global strategies for integrating epidemiology into the drug development process and enhancing the commercialization of BeiGene products.